

Cancer Programs Webinar: Just Ask study


February 16, 2022



Webinar Logistics

Cancer

- All participants are muted during the webinar
- Questions including technical issues you may be experiencing – should be submitted through the question pane
- Questions will be answered as time permits; additional questions and answers will be posted on the website
- Please complete the post-webinar evaluation you will receive via email





Agenda




- Welcome
- Addressing Tobacco Use in Cancer Patients
- Why are We Doing this Project?
- Plan-Do-Study-Act | Educational Resources
- Quality Improvement Project Evaluation Tools
- Review Surveys, Redcap, Application to Accreditation Standards
- Question and Answer
- Wrap up



Introducing Our Moderator





Laurie Kirstein MD, FACS
Attending Breast Surgeon
Memorial Sloan Kettering Cancer Center
Associate Professor
Cornell University Medical College
New Jersey



Panelist





Timothy Mullett, MD, MBA, FACS
Thoracic Surgery, University of Kentucky
Markey Cancer Center, Kentucky
Chair, Commission on Cancer
Kentucky



Jamie S. Ostroff PhD

Chief, Behavioral Science Service
Director, Tobacco Treatment Program
Department of Psychiatry & Behavioral Sciences
Memorial Sloan Kettering Cancer Center
New York




Introducing our Panelist





Graham Warren M.D., Ph.D., F.A.S.C.O.

Professor and Mary M. Gilbreth Endowed Chair of Clinical Oncology
Vice Chairman for Research in Radiation Oncology
Department of Radiation Oncology
Department of Cell and Molecular Pharmacology and Experimental
Therapeutics
Hollings Cancer Center
Medical University of South Carolina



Elisa Tong, M.D. M.A.

Professor of Medicine

Division of General Internal Medicine

UC Davis Health, California



Introducing our Panelist





Erin DeKoster Reuter

Accreditation Senior Manager, Cancer Programs

American College of Surgeons, Illinois





Achieving Quality Improvement In Cancer Programs

Addressing Tobacco Use in Cancer Patients
Timothy Mullett, MD, MBA, FACS







- Demonstration of effective quality improvement has been challenging or elusive in cancer programs
 - Quality Improvement Initiative Standard
 - Several different forms since 2012
 - Evidence-based strategies (DMAIC, PDSA, others)
 - Often not defined well in reports or in action
- Return to Screening PDSA
 - First effort to 'package the process'
 - Driven by universal challenge of COVID on screening
 - Offer program to all programs
 - Uniformly successful




Key Objectives



JAMA Oncology | Original Investigation

Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic

Ronald C. Chen, MD, MPH; Kevin Haynes, PharmD, MSCE; Simo Du, MBBS, MHS; John Barron, PharmD; Aaron J. Katz, PharmD, PhD



COVID-19 & CANCER NCI DIRECTOR'S REPOR

Sharpless: COVID-19 expected to increase mortality by at least 10,000 deaths from breast and colorectal cancers over 10 years

Prevent Unnecessary Cancer Deaths



Return To Screening Collaboration



Collaboration

American Cancer Society
Commission on Cancer (CoC)
National Accreditation Program for Breast Centers (NAPBC)

Goal: Accelerate Return To Screening

CoC and NAPBC enthusiastically embraced the concept of a prepared Quality Improvement Initiative

Over 900 projects were completed



Building on RTS PDSA



- Several models for QI confusing
- Follow PDSA
 - Familiar for programs
 - Reinforce process
- Narrow lane to achieve results
- Targeted interventions
 - Standardized with national partner
- Rapid development
 - 2022 timeline
- Consideration of future role of tobacco treatment in CoC Cancer Programs



Tobacco Use Assessment Collaboration



Collaboration

NCI – Cancer Center Cessation Initiative (C3I)
Commission on Cancer (CoC)
National Accreditation Program for Breast Centers (NAPBC)

Goal: Improve Fidelity of Tobacco Use Assessment in Cancer



Tobacco and Cancer Task Force Members



Graham Warren, MD, PhD	Medical University of South Carolina
lamas Hamis NAD	Western Surgical Group
James Harris, MD	CoC Accreditation Committee Chair
Daniel Boffa, MD	Yale School of Medicine
Daillei Bolla, Wib	CoC Quality Integration Committee Chair
Ellen Hahn, PhD	University of Kentucky College of Nursing
Audrey Darville, APRN, PhD	University of Kentucky College of Nursing
Laurie Kirstein, MD	Memorial Sloan Kettering
Laurie Kirstein, MD	CoC Education Committee Chair
Jamie Ostroff, PhD	Memorial Sloan Kettering
Jessica Burris, PhD	University of Kentucky College of Public Health
Sarah Shafir, MPH	American Cancer Society
Tim Mullett, MD	University of Kentucky Thoracic Surgery
Tilli Mullett, MD	CoC Chair
Elisa Tong, MD, MA	UC Davis Health
Rachel Shelton, ScD, MPH	Columbia University






Why are We Doing this Project?

Graham Warren M.D., Ph.D., F.A.S.C.O



Smoking and the Continuum of Cancer Care






Cancer Patients





2014 SGR: >400 studies, 500K patients 1990-2012

Effect	Associations	Median RR
Overall Mortality (159 studies)	87%	Current: 1.51 Former: 1.22
Cancer Mortality (58 studies	79%	Current: 1.61 Former: 1.03



Overall Mortality Among 129 studies, 2013-17

- Smoking at diagnosis with 61% increased risk
- Smoking at follow-up with 113% increased risk

Financial Effects of Smoking at Diagnosis

 Smoking after diagnosis adds ~\$3.4 billion in cancer treatment costs annually (2019 estimates)

Benefits of Smoking Cessation


- Smoking cessation AFTER diagnosis associated with 45% median reduction in mortality
- Smoking cessation AT ANY TIME reduces non-cancer mortality (heart disease, pulmonary disease, etc.)

2014 Surgeon General's Report 2020 Surgeon General's Report GW Warren, C3I Spring Meeting 2021




How Does this Compare with Other Practice Change?







Overall Survival with Pembro by PD-L1 status, Keynote-001 (Garon et al. NEJM 2015)



Overall Survival with Duvalumab, Pacific Trial (Antonia et al. NEJM 2018)



Overall Survival with Pembro, PD-L1 >50 Keynote-010 (Herbst et al. JTO 2021)



Smoking Cessation added to first line NSCLC treatment (Dobson-Amato et al. JTO 2015)




How Can We Begin to Address Smoking?



Deficiencies in Care

- Most institutions don't incorporate smoking into cancer care
- Most oncologists don't assist patients
- Most patients don't receive help
- Most patients continue to smoke after diagnosis



Evidence-Based Care

- The 5A's Model
 - Ask
 - Advise
 - Assess
 - Assist
 - Arrange
- The 3A's/AAR/AAC Model
 - Ask
 - Advise
 - Assist, Refer, or Connect
- Start by <u>JUST ASKing</u> all new patients about smoking

Warren and Simmons. Ch. 33 DeVita *Principles and Practice of Oncology* 11th ed. 2018



Purpose: JUST ASK All New Patients About Smoking



ASK

- Ask all new patients about smoking
- Identify current smoking

▼ <u>ADVISE</u>

- Continued smoking negatively affects cancer treatment
- Smoking cessation can improve survival

ASSIST, REFER, or CONNECT

- Clinicians can assist patients with quitting: counseling and medication
- Refer/Connect: institutional, community, or quitlines (1-800-QUIT-NOW)



Purpose: JUST ASK All New Patients About Smoking



ASK

- Ask all new patients about smoking
- Identify current smoking

↓ ADVISE

The purpose of this PDSA is to improve ASKing for all new cancer patients

Advising or Assisting is encouraged, but WILL NOT be measured

- Continued smoking negatively affects cancer treatment
- Smoking cessation can improve survival



ASSIST, REFER, or CONNECT

- Clinicians can assist patients with quitting: counseling and medication
- Refer/Connect: institutional, community, or quitlines (1-800-QUIT-NOW)





Plan-Do-Study-Act | Educational Resources

Elisa Tong, M.D. M.A.



Quality Improvement Project Schema



Part 1: Education

Participate in educational webinars as scheduled – encouraged but not required.

Part 2: Intervention

ASK all newly diagnosed cancer patients about smoking and report results:

- 1. Total number of newly diagnosed cancer patients seen.
- 2. Number of patients asked about smoking status.
- 3. Number of patients identified as currently smoking.

Part 3: Assessment

REDCap surveys due April 1, 2022, September 1, 2022 and February 1, 2023.





Step 1a: Assemble a team to discuss how assessment of smoking will be conducted

Identify and convene stakeholders to engage involved in ASKing about smoking



Step 1b: Discuss specific and achievable goals for your cancer program.

- Share resources about the importance of addressing smoking in cancer care
- Assess current workflow. Define how your cancer program will complete ASK reporting requirements.



Step 1c: Create a plan to improve ASKing for all new cancer patients.

- Select intervention strategies to improve ASKing about smoking.
- Schedule calendar holds to attend educational webinars and complete assessments.







- Attend educational webinars with team members and providers.
- Implement selected intervention strategies
- Complete baseline survey assessment & follow-up assessments
 - Baseline data can be obtained retrospectively from the prior month, quarter, or year as available at your site.
 - Report core QI metrics.
 - How many new patients were seen? (denominator)
 - Definition of "new patient" may include those presenting for cancer workup, diagnosis, or start of treatment.
 - How many new patients have smoking status assessed? (numerator)
 - Definition of smoking status is in Appendix 1.













 Monitor progress in ASKing about smoking status. Extract assessment data on a regular basis, preferably monthly from the electronic health record (EHR), to see if more patients are being ASKed about smoking.



 Meet with team members on a regular basis to discuss assessment data. Work to identify gaps, barriers, and systemic deficits related to ASKing (e.g., by patient characteristics, provider department, workflow, etc.).



• The ideal program target goal should be to increase ASKing by 20% over baseline or achieve a >90% overall ASKing rate among new cancer patients. The proposed program target goal is not a required compliance criteria to meet standards for this project, but members should endeavor to improve ASKing as much as reasonably possible within their center.







- Reflect on the success and challenges of the project.
- Refine intervention strategies with stakeholders and sustain the quality improvement.
- Present final results to the cancer committee.
- Consider future interventions to ASSIST patients with smoking cessation. Any site that wants to provide assistance to patients can refer patients to free state quit lines (1-800-QUIT-NOW), identify existing local smoking cessation programs, or assist patients directly with counseling and medications in clinic.









Implementation Strategies









PROVIDERS



SYSTEM



Smoking Status in the Electronic Health Record



Social History: Tobacco Use

- Current every day smoker
- Current some day smoker
- Former smoker
- Never smoker
- Smoker, current status unknown
- Unknown if ever smoked
- Heavy tobacco smoker
- Light tobacco smoker

Suggested script & definitions:

"Have you ever smoked in your life?"

NO = Never smoker

"When did you last smoke?"

≥ 30 days = Former smoker

"How much do you smoke?"

Daily = Current every day smoker

>10 cigarettes/day = Heavy smoker



For Providers





Smoking Causes Cancer

One out of every three cancer deaths in the U.S. is related to cigarette smoking. Smoking causes 12 types of cancer, including cancers of the lung. larynx, oral cavity and pharynx, espohagus, pancreas, bladder, stomach, liver, colon and rectum, kidney and renal pelvix, cervix, and acute myeloid leukemia (AML). Additionally, secondhand moke expourer causes lung cancer.

Research shows that, in both patients with cancer and cancer survivors, smoking:

- · Increases the risk of death, including death from cancer.
- Increases the risk for development of additional primary cancers which are smoking-related.
- May increase risk of cancer recurrence.
- May result in poorer treatment response and increased treatment-related toxicity.

Smoking Cessation Protects Against Cancer

Smoking cessation is one of the most important actions people who smoke can take to improve their health and reduce their risk for cancer. This is true for all people who smoke, regulations of age or smoking duration and intensity. For patients with cancer, studies suggest that quitting smoking can significantly reduce mortality and improve their prognosis.

Smoking cessation protects against cancer and benefits both patients with cancer and cancer survivors. Healthcare professionals, particularly those in oncology care, should treat patients' tobacco use and dependence.



Benefits of Smoking Cessation

- Reduces the risk of 12 different types of cancer, including lung, larynx, oral cavity and pharynx, esophagus, pancreas, bladder, stomach, colon and rectum, liver, cervix, kidney, and acute myeloid leukemia (AML).
- After cessation, the risk of developing cancer (compared to continued smoking) drops over time:
- 5 to 10 years after quitting: added risk* of cancers of the larynx, oral cavity, and pharynx drops by half.
- 10 years after quitting: risk of cancers of the bladder, esophagus, and kidney decreases.
- 10 to 15 years after quitting: added risk* of lung cancer drops by half.
- 20 years after quitting: risk of cancers of the larynx, oral cavity, pharynx, and pancreas drops to close to that of someone who does not smoke.
- 20 years after quitting: added risk* of cervical cancer drops by about half.

'The added risk of cancer above that of the general population which is linked to smoking.

Benefits of Smoking Cessation for Patients With Cancer

- ▶ Improves the prognosis of patients with cancer.
- ▶ May improve all-cause mortality in patients with cancer.

Clinical Interventions Work

Tobacco use and dependence is a chronic, relapsing condition that other requires repeated intervention and long-term support. Quitting can be hard, but evidence-based treatments (listed below) innovae success.

- Behavioral Counseling: Counseling can be in person (one-on-one or in a group) or over a telephone quittine. Text messaging and web-based interventions also help people quit smoking.
- Medication: Seven medications are approved by the U.S. Food and Drug Administration (FDA) for smoking costation (see text box).
- Combining Treatments: Counseling and medication are effective on their own, but using them together can more than double the chances of qualities, Combining long-acting NRT (patch) with whort-acting NRT loy, gorn, lizzenge) also increases the chances of qualiting.

FDA-Approved Medications

- Nicotine Replacement Therapy (NRT) reduces ricotine withdrawal symptoms and is available over the counter (patch, gwm, and iszempe) and by prescription (inhaler and maint sorae).
- Varenicline is a nicotine receptor partial agonist available only by prescription. It reduces ricotine withdrawal symptoms (including craving) and reduces the rewarding effects of cigarettes by blocking vicotinic receptors.
- Buprogian is a dopamine and nonpinephrine reuptake inhibitor with nicotine ecoptor artagenist properties. It reduces caying and other withdrawal symptoms and is available by prescription only.

The Entire Clinical Care Team Can Help

A team approach is the best way to treat tobacco use and dependence. Integrating treatment into the routine clinical workflow and engaging the entire healthcare team in treatment delivery can make a difference.



Advise Patients to Quit

- Talk to patients at every visit about their tobacco use. Even brief advice can influence a patient's decision to quit smoking.
- Advise patients that quitting is one of the most important things they can do to improve their health and prognosis.
- Remind patients that it is never too late to quit smoking. Quitting is beneficial at any age.
 Provide patients support, regardless of their madiness to quit.



Offer Patients Treatment

. Offer patients a combination of counseling and medications.



Refer Patients to Additional Support

Refer patients to creation records and programs in your health system and community. You can also refer them to telephone quistines (1-800-QUIT-NOW) and web- and text-based programs.



Follow Up With Patients

- Assess your patients' progress over time and provide additional support. It may take several attempts for them to quit smoking.
- Try new strategies, like new medications the patient haze't tried, medication combinations, or new approaches to handling triggers.
- Provide ongoing support and encourage patients to keep trying and not give up.

Smoking Cessation Resources for Clinicians

- CDC resources were cdc.gov/febaccettCP. Caring for Cancer Servivors Who Use Tobacco; available at work ofc.gov/cancer/servivors/health-care-providers/tobacco-use.htm
- # Million Hearts resources: Tehacca Treatment Protocol. Action Golds. and Change Package available
- millionhearts.hhs.gog

 Treating Tabacco Use and Dependence, Clinical Practice Guideline: 2008 Update 2008 lable at
- MEMBARIKAN D. U.S. Penerfice lawies last force Inhacea Smoking Constion in Adults, including Promest Women, Rehavioral and Pharmacotherapy interestions and label of membaricantiness releastable co. and
- National Comprehensive Cancer Network Guidelines for Smoking Consuling available at www.nccn.org



89-25-2020

https://www.cdc.gov/tobacco/patient-care/caresettings/pdfs/cdc-osh-hcp-oncology-factsheet-508.pdf



For Patients



AMERICAN COLLEGE OF SURGEONS




Smoking Increases Your Risk of Heart and Breathing Problems'

Smoking increases the mucus in the airways and decreases your ability to fight infection. It also increases the risk of pneumonia and other breathing problems. Airway function improves if you quit 8 weeks before your procedure.

The nicotine from cigarettes can increase your blood pressure, heart rate, and risk of arthythmias (irregular heart beat). The carbon monoxide in cigarettes decreases the amount of oxygen in your blood. Quitting at least 1 day before your operation can reduce your blood pressure and irregular heart beats.

Smokers have an increased risk of blood clots and almost twice the risk of a heart attack as nonsmokers.





*Breathing problems such as coughing, wheezing, and low oxygen levels are increased in smokers.


A smoker is 2.2 times more likely to get pneumonia than a nonsmoker. So if a nonsmoker has a 10 percent risk, a smoker has a 22 percent risk.²



AMERICAN COLLEGE OF SURGEONS | DIVISION OF EDUCATION Blanded Surgical Education and Training for Life*

Quit Smoking Before Your Operation

Smoking Increases Your Risk of Wound Complications³



Oxygen is needed for your tissues to heal. Smoking can decrease the amount of blood, oxygen, and nutrients that go to your surgical site. A smoker has almost 4 times the risk of tissue damage at the surgical site.⁴

Smoking interferes with all phases of wound healing, it also decreases the ability of the cells to kill bacteria and fight infection. Having a wound infection increases the average length of stay by 2 to 4 days. Quilting 4 weeks before a surgical procedure reduces postoperative complications by 20 to 30 percent.

Studies identify that patients who smoke have:


- Increased wound infection and splitting open of the wound in patients having general surgery or hip and knee replacements.
- Increased sternal (chest bone) wound infection after coronary bypass surgery.
- Increased wound necrosis (tissue death) after mastectomy and breast reconstruction.
- Increased incisional and recurrent inguinal hemias.
- Lack of bone healing after orthopaedic surgery.
- Significantly higher rates of deep surgical site infections and re-operation following plastic surgery.⁵
- Greater pain intensity and higher amounts of narcotics needed for pain control.

Smoking Cessation at the Time of Surgery May Be the Best Time to Quit

- Smoking cessation counseling before a surgical procedure increases the quit rate.
- Multiple approaches (counseling plus medication and quit lines) work best to help you stay quit for life.
- You will most likely be receiving pain medication after
 surgery which will decrease your withdrawal affects.



Smoking Increases Your Risk of Cancer Recurrence⁶



Smoking is known to cause 12 different types of cancer. Clgarette smoking is the number one cause of lung cancer.⁶

Secondhand smoke causes lung cancer in both children and adults who don't smoke.⁷

AMERICAN COLLEGE OF SURGEONS - SURGICAL PATIENT EDUCATION - www.facs.org/patienteducation

Treatment

The oldewing treatment are prevent to be effective for market who was the big rugs. It is most to discuss with your and the property of the propert



EDUCATION PROGRAM

For Peers: NCI Cancer Center Cessation Initiative – 52 Centers







https://cancercontrol.cancer.gov/brp/tcrb/cancercenter-cessation-initiative



Quality Improvement Project

Evaluation Tools

Jamie Ostroff, PhD



Appendix 3: Assessment Form



Overall goal is to describe current practices, barriers, strategies and readiness to adopt smoking cessation assessment and treatment at your cancer care setting.

Section I.	Background Information	15 items
Section II. (Current Smoking Assessment and Treatment Practices	12 items
Section III. I	mplementation Barriers	11 items
Section IV. I	mplementation Strategies	7 items
Section V. C	Organizational Prioritization	4 items
Section VI. C	Clinical Data Reporting and Metrics (ASK)	4 items

ACS AMERICAN COLLEGE OF SURGEONS

60 mins

Estimated Time for Completion of Sections I. to V.

Section I. Background Information



Rationale

- To describe your cancer care setting
- These questions focus on describing relevant setting characteristics and contextual background

Screen Shot/Sample Items

Appendix 3: REDCap Evaluation Tool

These data are collected at baseline (by April 1, 2022) and will be evaluated again by September 1 2022 and February 1, 2023 after initiation of the QI project at your site.

Section I. Background Information. The section provides background information about your site.

Date of completion of form	_
Name of individual completing form	
Email of individual completing form	
Name of CoC Facility	
Facility CoC ID Number (FIN #)	
CoC Cancer Program Category	 Academic Comprehensive Cancer Program
	 Community Cancer Program
	 Comprehensive Community Cancer Program
	 Freestanding Cancer Center Program
	 Hospital Associate Cancer Program
	 Integrated Network Cancer Program
	 NCI-Designated Comprehensive Cancer
	Program
	 NCI-Designated Network Cancer Program
	 Pediatric Cancer Program
	 Veterans Affairs Cancer Program



Section II. Current Smoking Assessment and Treatment Practices



Rationale

To describe your current clinical practices for The following questions ask about tobacco assessment and treatment services that are currently assessing smoking status and providing smoking cessation treatment to patients who currently smoke

Screen Shot/Sample Items

Section II. Smoking Assessment and Smoking Cessation Practices

available for newly diagnosed cancer patients treated at your setting. Please indicate how frequently your oncology care providers do the following during new visits:

	Always	Most of the time	Sometimes	Rarely	Never
ASK patients whether they currently smoke cigarettes or use other types of tobacco products.					
ADVISE patients who smoke to quit.					
ASSIST patients who smoke to quit.					
Decument emoking status/tabases use in					



Section III. Implementation Barriers



Rationale

➤ To describe your perceived challenges in assessing smoking status and providing smoking cessation treatment to patients who currently smoke

Screen Shot/Sample Items

Section III. Implementation Barriers

To what extent do you perceive these barriers for promoting smoking cessation among cancer patients who are current smokers at your cancer care setting?

	Completely Agree	Somewhat Agree	Neither Agree or Disagree	Somewhat Disagree	Completely Disagree
Lack of staff time for counseling.			Disagree)
Lack of staff training in smoking cessation interventions.					



Section IV. Implementation Strategies



Rationale

➤ To consider the feasibility and effectiveness of several potential implementation strategies for improving delivery of smoking assessment and treatment at your setting

Screen Shot/Sample Items

Section IV. Implementation Strategies

The next set of questions focus on the potential implementation strategies for actively improving the delivery of smoking cessation treatment at your cancer care setting. Please read each statement and indicate which ones seem feasible and/or effective for your site. Which strategies do you think would be feasible and effective in improving delivery of smoking assessment and treatment at your site (check all that apply):

, , , , , , , , , , , , , , , , , , , ,		
	Feasible	Effective
Staff/Clinician Training.		
Gain support of site leadership.		



Section V. Organizational Priority and Readiness



Rationale

> To consider the organizational readiness for The next set of questions focus on the organizational readiness for delivering smoking cessation improving delivery of smoking assessment and treatment at your setting

Screen Shot/Sample Items

Section V. Organizational Readiness and Priority

treatment at your cancer care setting. Please read each statement and indicate which response best reflects your setting's readiness to implement tobacco use assessment and treatment.

	Agree	Somewhat Agree	Neither Agree or Disagree	Somewhat Disagree	Disagree
People who work here are committed to implementing tobacco use assessment and treatment.					
People who work here are motivated to implement tobacco use assessment and treatment.					



Section VI. Clinical Data Reporting and Metrics (ASK)



Rationale

➤ To provide clinical data on the quality of assessing smoking status at your cancer care setting during pre-specified timeframes

Screen Shot/Sample Items

Section VI. Clinical Data Reporting and Metrics (ASK):

These data are collected at baseline (by April, 1, 2022) and again by September 1, 2022 and February 1, 2023 after initiation of the QI project at your site

representation of the Grand	
For this reporting period, please extract	the following time periods:
data (numerator and denominator) and	**January 1 to December 31, 2021 by April 1, 2022 in
report ASK metrics from	the baseline REDCap survey;
	**January 1 – June 30, 2022 in the second REDCap
	due September 1, 2022; and
	**July 1 - December 31, 2022 in the third REDCap
	due February 1, 2023.
What clinical setting are you analyzing?	Choose one reply
	 A single clinical setting (describe)
	 Multiple clinical settings (describe)
	 All cancer patients seen at this facility
How many new patients were seen during	
this baseline period? (DENOMINATOR)	
How many new patients were ASKed about	
smoking during a cancer workup,	
diagnosis, or initial consultation for cancer	
treatment? (NUMERATOR)	

How many patients reported current	
smoking? (NUMERATOR)	





Review Surveys, Redcap, Application to Accreditation Standards

Erin DeKoster Reuter



Credit for CoC and NAPBC Standards



Completing the PDSA QI project will fulfill the following CoC Standards:

- Quality Improvement Initiative 7.3
- Cancer Prevention Event 8.2
- Clinical Research Accrual 9.1

Completing the PDSA QI project will fulfill the following NAPBC Standards:

- Cancer Prevention, Education, and Early Detection Programs 4.1
- Quality and Outcomes 6.1 (counts toward one of two studies)

Programs can claim either CoC credit or NAPBC credit, but not both.



A QUALITY PROGRAM of the AMERICAN COLLEGE OF SURGEONS



A QUALITY PROGRAM of the AMERICAN COLLEGE OF SURGEONS



Next Steps



Full study protocol will be posted to the ACS Cancer Programs website by early March

The recording of today's webinar & a FAQ will be posted to the web page

The baseline REDCap assessment/survey will be released in early March to be completed by participating programs by **April 1, 2022**

 Additional assessments/surveys will need to be completed by September 1, 2022 and February 1, 2023 to count towards compliance

Three webinars are planned throughout the year to support the study (attendance is encouraged but not required)

The above will be communicated via emails and in the Cancer Programs Newsletter



Conclusion



- Tobacco use in cancer patients has a negative impact on:
 - Compliance
 - Recurrence Rates
 - Overall Mortality
- Tobacco treatment during cancer treatment improves outcomes
- Assessment and documentation of tobacco use in the cancer care setting is variable
- The PDSA Quality Improvement Initiative is designed to help us take the FIRST step in getting cancer patients at risk for tobaccorelated complications the treatment they need

Question and Answer











Physician's, Nurse's, or Certified Tumor Registrar's Cancer Programs offers free education credit courses on our learning management system (LMS). Below is a short list of some of our courses at <u>Learning.facs.org</u>:

- AJCC yc Stage Classification—When and How to Use
- Registrar's Guide to Updating Radiation Data Items
- AJCC Cervix Uteri Version 9 Cancer Staging System
- *Survivorship Program: Standard 4.8
- *Operative Standards for Cancer Surgery: Standards 5.3-5.8
- *Taking the Mystery Out of QI Projects Per Standard 7.3: A How-to Guide
- *Oncology Nursing Credentials: Standard 4.2
- NAPRC: Practical Tips, Pearls, and Advice from the Trenches PART 1 and 2
- *Surgical Emergencies in Advanced Cancer Patients
- *Surgical Oncology for the General Surgeon
- *Pelvic MRI for Rectal Cancer: Tips on Interpretation
- CAnswer Forum LIVE 2019-2021



^{*}CME offered